Medulloblastoma News and Research

RSS

Specific stem cell protein found to be involved in the recurrence of medulloblastoma

The malignant brain tumor type medulloblastoma can become resistant to therapy which can cause relapse. Researchers at Uppsala University have discovered a certain protein that makes tumor cells resting and insensitive to radiation treatment.

28 Oct 2022

Medulloblastomas originate much earlier in pregnancy than previously thought and may be preventable

An aggressive type of pediatric brain tumor, medulloblastoma, exists in a pre-malignant form at birth after initially developing during the first or second trimester of pregnancy, according to a new international study.

21 Sep 2022

Scientists track origins of group 3 and group 4 medulloblastoma to the rhombic lip

Scientists at St. Jude Children's Research Hospital have discovered which cells give rise to certain high-risk groups of medulloblastoma.

21 Sep 2022

Hollings researcher awarded grant to continue research into mechanisms behind medulloblastoma relapse

When MUSC Hollings Cancer Center researcher Jezabel R. Blanco, Ph.D., began studying neurosciences, first as a graduate student and later as a postdoctoral fellow, her research was focused on understanding the mechanisms underlying brain disease, both in the context of neurodegeneration and cancer, but mostly from a basic research angle.

20 Jul 2022

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Effective and safe treatments are needed for medulloblastoma-;the most common type of cancerous brain tumor in children-;especially for patients whose cancer has spread to the spinal cord.

14 Jul 2022

Nemours Children’s Health scientists receive two NIH grants to advance pediatric cancer research

Nemours Children's Health researchers have received two grants from the National Institutes of Health (NIH) totaling $5 million.

12 Apr 2022

Aggressive brain tumor in children can be identified by analyzing cerebrospinal fluid

It may be possible to identify the presence of an aggressive brain tumor in children by studying their cerebrospinal fluid, according to new research led by Johns Hopkins Kimmel Cancer Center investigators.

2 Mar 2022

Drug combo delivered in a nanoparticle formulation extends the survival of mice with medulloblastoma

UNC Lineberger Comprehensive Cancer Center researchers have demonstrated that a novel combination of two drugs that act as targeted inhibitors, delivered in a nanoparticle formulation, extend the survival of mice with medulloblastoma.

27 Jan 2022

Study opens up prospects for using virotherapy to treat central nervous system tumors

In a study conducted at the University of São Paulo's Human Genome and Stem Cell Research Center (HUG-CELL) in Brazil, serial systemic injections of zika virus into mice with brain tumors destroyed the cancer without causing neurological damage or injuring other organs, and increased the animals' survival rate.

11 Jan 2022

Researchers develop a new test to more easily diagnose medulloblastoma

Researchers at the University of British Columbia and BC Cancer, in partnership with BC Children's Hospital Research Institute, have developed a new test to more easily diagnose medulloblastoma, the most common malignant childhood brain tumor.

1 Nov 2021

Cell-free DNA can help detect measurable residual disease in children with medulloblastoma

Scientists at St. Jude Children's Research Hospital have shown that cell-free DNA from cerebrospinal fluid (CSF) can be used to detect measurable residual disease (MRD) in children treated for the brain tumor medulloblastoma.

21 Oct 2021

Gateway for Cancer Research funds EORTC 1634-BTG trial in post-pubertal brain tumor patients

Gateway for Cancer Research℠ awards grant to the EORTC 1634- Brain Tumour Group (BTG) academic trial in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I).

27 Jul 2021

Genetic map reveals potential new treatment for aggressive childhood brain tumor

A genetic map of an aggressive childhood brain tumor called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease.

7 Jul 2021

Research shines new light on deadly medulloblastoma metastases

With advances in medical science driving progress against childhood brain tumors, today three out of four young patients survive at least five years beyond diagnosis. However, the outcomes look grim when malignant cells spread, or metastasize.

29 Jun 2021

Study identifies the cell of origin of medulloblastoma

The study was conducted by an international collaboration involving the research team led by Luca Tiberi of the Armenise-Harvard Laboratory of Brain Cancer at the Department of Cellular, computational and integrative biology - Cibio of UniTrento, the Paris Brain Institute-Institut du Cerveau at Sorbonne Université in Paris, the Hopp Children´s Cancer Center (KiTZ) in Heidelberg, Germany, and Sapienza University in Rome.

24 Jun 2021

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

A new class of drugs that inhibits a "master switch" involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai.

22 Jun 2021

Study provides treatment options for children with average risk medulloblastoma

Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine.

11 Jun 2021

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.

21 May 2021

Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors

RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways.

7 May 2021

Maternal exposure to pesticides may lead to central nervous system tumors during childhood

Research published in the peer-reviewed journal Environmental Research suggests that exposure during pregnancy to a wide variety of pesticides may lead to the development of central nervous system tumors during childhood.

3 Apr 2021